EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma

Weilong Zhang, Bangquan Ye iD, Yang Song, Ping Yang, Wenzhe Si, Hairong Jing, Fan Yang, Dan Yuan, Zhihong Wu, Jiahao Lyu, Kang Peng, Xu Zhang und 12 weitere

Clinical and Translational Medicine · 2025-01 · 15 (1)

DOI: 10.1002/ctm2.70174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 07.01.2025. Verfasst von Weilong Zhang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multi‐omics features of cell‐free DNA (cfDNA) can effectively improve the performance of non‐invasive early diagnosis and prognosis of cancer. However, multimodal characterization of cfDNA remains technically challenging.

Methods

We developed a comprehensive multi‐omics solution (COMOS) to specifically obtain an extensive fragmentomics landscape, presented by breakpoint characteristics of nucleosomes, CpG islands, DNase clusters and enhancers, besides typical methylation, copy number alteration of cfDNA. The COMOS was tested on 214 plasma samples of diffuse large B‐cell lymphoma (DLBCL) and matched healthy controls.

Results

For early diagnosis, COMOS improved the area under the curve (AUC) value to .993 compared with the individual omics model, with a sensitivity of 95% at 98% specificity. Detection sensitivity achieved 91% at 99% specificity in early‐stage patients, while the AUC values of the individual omics model were 0.942, 0.968, 0.989, 0.935, 0.921, 0.781 and 0.917, respectively, with lower sensitivity and specificity. In the treatment response cohort, COMOS yielded a superior sensitivity of 88% at 86% specificity (AUC, 0.903). COMOS has achieved excellent performance in early diagnosis and treatment response prediction.

Conclusions

Our study provides an effectively improved approach with high accuracy for the diagnosis and prognosis of DLBCL, showing great potential for future clinical application. Key points A comprehensive multi‐omics solution to specifically obtain an extensive fragmentomics landscape, presented by breakpoint characteristics of nucleosomes, CpG islands, DNase clusters and enhancers, besides typical methylation, copy number alteration of cfDNA. Integrated model of cfDNA multi‐omics could be used for non‐invasive early diagnosis of DLBCL. Integrated model of cfDNA multi‐omics could effectively evaluate the efficacy of R‐CHOP before DLBCL treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseHumansFemaleMaleMiddle AgedAgedAdultEarly Detection of CancerPrognosisCell-Free Nucleic AcidsRituximabBiomarkers, TumorDoxorubicinEarly DiagnosisCyclophosphamideMultiomics

Stichwörter der Autor:innen

DLBCLcfDNAearly diagnosisintegrated modelmulti‐omicstreatment prediction

Substanzen

Cell-Free Nucleic AcidsRituximabBiomarkers, TumorDoxorubicinCyclophosphamide

Autor:innen und Institutionen

  • Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
  • BOE Technology Group Co., Ltd, Beijing, China.
  • Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China.

ORCID-Profile: Bangquan Ye, Hongmei Jing

Zitieren

APA

Zhang, W., Ye, B., Song, Y., Yang, P., Si, W., Jing, H., Yang, F., Yuan, D., Wu, Z., Lyu, J., Peng, K., Zhang, X., Wang, L., Li, Y., Liu, Y., Wu, C., Hao, X., Zhang, Y., Qi, W., …, & Li, Y. (2025). Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma. Clinical and Translational Medicine, 15(1). https://doi.org/10.1002/ctm2.70174

Vancouver

Zhang W, Ye B, Song Y, Yang P, Si W, Jing H, et al. Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma. Clinical and Translational Medicine. 2025;15(1). doi:10.1002/ctm2.70174

BibTeX
@article{Zhang2025,
  author = {Zhang, Weilong and Ye, Bangquan and Song, Yang and Yang, Ping and Si, Wenzhe and Jing, Hairong and Yang, Fan and Yuan, Dan and Wu, Zhihong and Lyu, Jiahao and Peng, Kang and Zhang, Xu and Wang, Lingli and Li, Yan and Liu, Yan and Wu, Chaoling and Hao, Xiaoyu and Zhang, Yuqi and Qi, Wenxin and Wang, Jing and Dong, Fei and Zhao, Zijian and Jing, Hongmei and Li, Yanzhao},
  title = {Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  volume = {15},
  number = {1},
  doi = {10.1002/ctm2.70174}
}
Kostenlos starten →